How to translate text using browser tools
28 October 2020 Mesenchymal stromal cell-derived extracellular vesicle therapy prevents preeclamptic physiology through intrauterine immunomodulation
Elizabeth S. Taglauer, Angeles Fernandez-Gonzalez, Gareth R. Willis, Monica Reis, Vincent Yeung, Xianlan Liu, S. Alex Mitsialis, Stella Kourembanas
Author Affiliations +
Abstract

Human umbilical cord-derived mesenchymal stromal cells (MSCs) are a widely recognized treatment modality for a variety of preclinical disease models and have been transitioned to human clinical trials. We have previously shown in neonatal lung disease that the therapeutic capacity of MSCs is conferred by their secreted extracellular vesicles (MEx), which function primarily through immunomodulation. We hypothesize that MEx have significant therapeutic potential pertinent to immune-mediated gestational diseases. Of particular interest is early-onset preeclampsia, which can be caused by alterations of the maternal intrauterine immune environment. Using a heme-oxygenase-1 null mouse model of pregnancy loss with preeclampsia-like features, we examined the preventative effects of maternal MEx treatment early in pregnancy. Heme oxygenase-1 null females (Hmox1–/–) or wild-type control females were bred in homozygous matings followed by evaluation of maternal and fetal parameters. A single dose of MEx was administered intravenously on gestational day (GD)1 to Hmox1–/– females (Hmox1–/– MEx). Compared with untreated Hmox1–/– females, Hmox1–/– MEx-treated pregnancies showed significant improvement in fetal loss, intrauterine growth restriction, placental spiral artery modification, and maternal preeclamptic stigmata. Biodistribution studies demonstrated that MEx localize to a subset of cells in the preimplantation uterus. Further, mass cytometric (CyTOF) evaluation of utero-placental leukocytes in Hmox1–/– MEx versus untreated pregnancies showed alteration in the abundance, surface marker repertoire, and cytokine profiles of multiple immune populations. Our data demonstrate the therapeutic potential of MEx to optimize the intrauterine immune environment and prevent maternal and fetal sequelae of preeclamptic disease.

Summary sentence

Antenatal administration of human umbilical cord mesenchymal stromal cell-derived extracellular vesicles prevents pregnancy loss, fetal growth restriction, and preeclamptic physiology through multiparameter modulation of intrauterine leukocytes.

© The Author(s) 2020. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Elizabeth S. Taglauer, Angeles Fernandez-Gonzalez, Gareth R. Willis, Monica Reis, Vincent Yeung, Xianlan Liu, S. Alex Mitsialis, and Stella Kourembanas "Mesenchymal stromal cell-derived extracellular vesicle therapy prevents preeclamptic physiology through intrauterine immunomodulation," Biology of Reproduction 104(2), 457-467, (28 October 2020). https://doi.org/10.1093/biolre/ioaa198
Received: 12 June 2020; Accepted: 23 October 2020; Published: 28 October 2020
KEYWORDS
biologic therapeutics
dendritic cells
extracellular vesicles
fetal growth restriction
immunomodulation
macrophages
mesenchymal stromal cells
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top